Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder
Збережено в:
Namchuk, A.B., et al., Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder. Adar, volume 2, 2022, p. 1-16.
Ref.
588688
Локація:
SIIS Archivo
Palabras clave:
Trastornos, Discapacidad, Depresión, Salud mental, Unión Europea
Trastornos, Discapacidad, Depresión, Salud mental, Unión Europea
Короткий огляд:
Rates of major depressive disorder (MDD) are disproportionally high in subjects with opioid use disorder (OUD) relative to the general population. MDD is often more severe in OUD patients, leading to compliance issues with maintenance therapies and poor outcomes
Rates of major depressive disorder (MDD) are disproportionally high in subjects with opioid use disorder (OUD) relative to the general population. MDD is often more severe in OUD patients, leading to compliance issues with maintenance therapies and poor outcomes
Схожі ресурси: Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder
- Comparing barriers to mental health treatment and substance use disorder treatment among individuals with comorbid major depression and substance use disorders
- Major depression and treatment response in adolescents with ADHD and substance use disorder
- COMORBIDITY BETWEEN DSM-IV ALCOHOL USE DISORDERS AND MAJOR DEPRESSION: RESULTS OF A NATIONAL SURVEY
- SUBSTANCE-INDUCED AND INDEPENDENT MAJOR DEPRESSIVE DISORDER IN TREATMENT-SEEKING ALCOHOLICS: ASSOCIATIONS WITH DYSFUNCTIONAL ATTITUDES AND COPING
- CONCURRENT ANXIETY AND SUBSTANCE USE DISORDERS AMONG OUTPATIENTS WITH MAJOR DEPRESSION: CLINICAL FEATURES AND EFFECT ON TREATMENT OUTCOME
- PRACTICE GUIDE FOR MAJOR DEPRESSIVE DISORDER IN ADULTS